Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
about
Targeted therapies in sarcomas: challenging the challengeTargeting the insulin growth factor receptor 1The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyThe insulin-like growth factor system in cancerChildren's Oncology Group's 2013 blueprint for research: bone tumorsHeterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibodyPotential approaches to the treatment of Ewing's sarcomaIGF-IR Targeted Therapy: Past, Present and FutureMolecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway BlockadeThe Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated ProteinsModeling the Insulin-Like Growth Factor System in Articular CartilageMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugEarly phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategyThe evolution of systemic therapy in sarcoma.Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyPhase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupInsulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group.Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013.R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axisInsulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Have we overestimated the benefit of human(ized) antibodies?Targeted Therapy of Ewing's Sarcoma.New therapeutic targets in soft tissue sarcoma.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers.Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationInsulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.Epidemiology and therapies for metastatic sarcomaEmerging therapies for adult soft tissue sarcoma.Emerging therapeutic targets for synovial sarcoma.Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directionsThe combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trialTargeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsAnticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
P2860
Q21285014-F64B22B6-95AB-4EEB-92D2-922C7D4A264DQ24633750-51A34096-6D2B-4B9F-9979-F567214CB25FQ27000467-3FAD99BB-8C3B-4361-BF24-610D0586B567Q27013945-1D4EC82A-25CB-4A07-9FDD-2334D92043DCQ27027664-793168E5-CFCA-4A75-B8B0-DD750D1BD6ABQ27306977-57379AB8-1070-424D-96F8-1BBF22FC7E2DQ28072744-EAA5277F-8A32-4D6B-AC10-83B626C95563Q28082127-D9EA17E7-F663-44DE-9D81-9A0ECDE1C0B0Q28088432-BB2A3288-139D-479F-92E0-71BFB046EC53Q28088661-B96428F2-6244-4473-B66E-B4E5EDD0DA3FQ28534346-408435EC-2032-4FD1-BFAD-BCD0D7B20318Q28538155-FAC520D6-565D-43FE-8F9E-EF6B04B7548AQ30234441-2D3781DA-1C46-455E-8716-30D7E62D72ECQ30540343-531CA00F-D1D7-4A87-91BE-719B48210138Q33274710-9C0A9975-62A7-45A0-82F0-BA349FD83FA4Q33396217-C19D0BA4-2F69-404E-8698-B3343E34FFC2Q33397796-BA9F91CD-C5A9-4C93-8DA1-AB40BE49A925Q33398810-B48407C5-E312-4E27-B0AE-BAE0DE5343FFQ33400495-7287547E-B273-4337-817B-8B4BC97082B2Q33559559-F2DCC62D-F52A-4FDC-B9C7-CE082AA05A18Q33873775-4F2E99FC-94C0-4AD5-9095-A54A23781536Q33910609-923CEE3A-446B-4AAC-B68B-AB2F2813F03CQ34038664-05A12CE8-4A22-45A1-8D15-4E413A05FADEQ34055933-9FCFE1FC-E8B9-4E07-8B1E-80ACF7FF78E4Q34110523-1AD9ADAA-9B85-4DD4-B771-6508908EB09DQ34142714-F778A01E-88E7-48FE-B1F7-B51ADC50EF51Q34262377-6A901284-8D14-41BB-8D51-C2EDE06662CBQ34267924-8FCF9ED5-8951-4B92-89F3-E0D45C2F570EQ34336988-D20F0350-7159-4C50-A406-68F333EF07DBQ34348691-DAC45F82-9E0A-4049-B848-A31DA583CCDAQ34387886-66CB0DE5-F058-43D2-AFDD-EF66F4BF810AQ34391968-BB67453D-3C19-4D96-A661-2AED40908B84Q34499662-579D1663-D680-409B-BF0B-6F8C191099FAQ34652142-F88D20CF-EBC2-4626-90EA-050BEF38A82DQ34659806-A4E1B7CF-9A84-4D60-B81A-12C5B2B72462Q34660607-45DBE2D5-1D31-42AB-8534-75A95F252689Q34787772-7F02F111-20FD-4196-A13B-792D5D07B02CQ34984126-4B05232F-90BB-4841-BFDF-B17C9EA50D13Q35013284-99829E82-CEAD-4C5F-B67F-4E754ED5EF1CQ35050195-71F96D9F-7FF2-4DCD-8A2C-756335BCB691
P2860
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@ast
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@en
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@nl
type
label
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@ast
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@en
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@nl
prefLabel
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@ast
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@en
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@nl
P2093
P2860
P1433
P1476
Safety, pharmacokinetics, and ...... hase 1 expansion cohort study.
@en
P2093
Antonio Gualberto
David Olmos
Donghua Yin
Francis P Worden
Gretchen N Batzel
Ian Judson
Johann S de Bono
Kathryn Pritchard-Jones
L Rhoda Molife
M Luisa Paccagnella
P2860
P304
P356
10.1016/S1470-2045(09)70354-7
P577
2009-12-23T00:00:00Z